Neurologic complications of immune checkpoint inhibitors.
Haugh AM, Probasco JC, Johnson DB.
Expert Opin Drug Saf. 2020 Apr;19(4):479-488. doi: 10.1080/14740338.2020.1738382. Epub 2020 Mar 11.
PMID:32126176
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M.
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
PMID:34166502
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.
J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.
PMID:29162153
Allergens.
Erwin EA, Platts-Mills TA.
Immunol Allergy Clin North Am. 2005 Feb;25(1):1-14. doi: 10.1016/j.iac.2004.09.008.
PMID:15579361
Nevrologiske komplikasjoner ved bruk av immunsjekkpunkthemmere.
Nes MS, Flobak Å, Vedeler C.
Tidsskr Nor Laegeforen. 2025 Aug 21;145(10). doi: 10.4045/tidsskr.24.0600. Print 2025 Sep 9.